NCT05589337

Brief Summary

In recent years, the number of people with symptoms of depression or anxiety are on the rise. The aims of the prospective randomized study are: (1) to examine the effects of Baduanjin breathing training on reducing symptoms of depression or anxiety, and (2) to explore the correlates between improvements of depression or anxiety symptom and changes of lung functions.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
15mo left

Started Jul 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress80%
Jul 2021Jul 2027

Study Start

First participant enrolled

July 1, 2021

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

October 17, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 21, 2022

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2026

Expected
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 30, 2027

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

5.5 years

First QC Date

October 17, 2022

Last Update Submit

April 23, 2026

Conditions

Keywords

BaduanjinDepressionAnxietyRandomized controlled trial

Outcome Measures

Primary Outcomes (2)

  • 17-item Hamilton Depression Rating Scale

    The HAMD-17 is a clinician-rated assessment (structured interview) of patients' depressive symptoms. Questions focus on depressive symptoms during the past 7 days, and higher cumulative scores indicate more severe depression.

    Change from Baseline HAMD-17 at 16 weeks

  • 14-item Hamilton Anxiety Rating Scale

    The HAMA-14 is a clinician-rated assessment (structured interview) of patients' anxious symptoms. Questions focus on anxious symptoms during the past 7 days, and higher cumulative scores indicate more severe anxiety.

    Change from Baseline HAMA-14 at 16 weeks

Secondary Outcomes (9)

  • Depression, Anxiety and Stress Scale-21 item

    Change from Baseline DASS-21 at 8 weeks

  • Depression, Anxiety and Stress Scale-21 item

    Change from 8 weeks DASS-21 at 16 weeks

  • Vital capacity

    Change from Baseline VC at 16 weeks

  • Forced vital capacity

    Change from Baseline FVC at 16 weeks

  • FVC percentage of predicted normal values

    Change from Baseline FVC% at 16 weeks

  • +4 more secondary outcomes

Study Arms (2)

Baduanjin intervention group

EXPERIMENTAL

Participants randomized to Baduanjin intervention group receive health education plus a Baduanjin training program. The Baduanjin training program was a 16-week, instructor-led group training program that offers breathing training as a core skill.

Behavioral: BaduanjinBehavioral: Health education

Health education control group

ACTIVE COMPARATOR

Participants randomized to the health education control group only receive health education and no additional training program.

Behavioral: Health education

Interventions

BaduanjinBEHAVIORAL

The Baduanjin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

Also known as: Eight-section Brocade
Baduanjin intervention group

Health education is provided by psychologist and TCM doctor, including work, rest, diet and other basic programs.

Baduanjin intervention groupHealth education control group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject with depression or anxiety symptom diagnosed by ICD-10.
  • Depression 7≤HAMD-17≤29,anxiety 7≤HAMA-14≤29.
  • Subject has a clear mind and the ability to read, to talk and to communicate.
  • Subject agrees to participate in this study and sign to the informed consent.

You may not qualify if:

  • Subject with bipolar disorder, psychotic disorder, organic mental disorder and cognitive disorder.
  • Subject with alcohol abuse, substance dependence and suicidal behavior in past-year.
  • Subject has severe somatic disease.
  • Subject is pregnant or lactating women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai Qigong Research Institute

Shanghai, Shanghai Municipality, 021, China

RECRUITING

MeSH Terms

Conditions

DepressionAnxiety Disorders

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorMental Disorders

Study Officials

  • Xiaoting Zhao

    Shanghai Qigong Research Institute

    STUDY CHAIR
  • Ying Lu

    Shanghai Qigong Research Institute

    PRINCIPAL INVESTIGATOR
  • Jie Li

    Shanghai University of Traditional Chinese Medicine

    STUDY DIRECTOR

Central Study Contacts

Ying Lu, Master

CONTACT

Xiaoting Zhao

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The outcome assessors were blinded to the group allocation of the participants.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a 16-week, randomized controlled trial. Patients with depression and anxiety symptoms are randomized to either Baduanjin intervention group or health education control group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Associate

Study Record Dates

First Submitted

October 17, 2022

First Posted

October 21, 2022

Study Start

July 1, 2021

Primary Completion (Estimated)

December 30, 2026

Study Completion (Estimated)

July 30, 2027

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations